

# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Pexidartinib (Turalio)

### Notes:

- Pexidartinib has a Boxed Warning for hepatotoxicity – it can cause serious and potentially fatal liver injury.
- Pexidartinib is available only through a restricted program called the TURALIO Risk Evaluation and Mitigation Strategy (REMS) Program.

**Initiation (new start) criteria:** Non-formulary **pexidartinib (Turalio)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Oncology/Hematology
- Diagnosis of tenosynovial giant cell tumor (TGCT)
- Patient is symptomatic (severe morbidity or functional limitations) and not amenable to improvement with surgery